Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Not Yet Opened 05-11 16:00:00 EDT

41.02

-0.01

-0.02%

盘后41.07

+0.05+0.12%

18:58 EDT

High41.06	Low41.02	Vol9.02M
Open41.03	D1 Closing41.03	Amplitude0.10%
Mkt Cap5.24B	Tradable Cap3.20B	Total Shares127.83M
T/O370.16M	T/O Rate11.55%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":41.02,"timestamp":1778529600000,"preClose":41.03,"halted":0,"volume":9021713,"hourTrading":{"tag":"盘后","latestPrice":41.07,"preClose":41.02,"latestTime":"18:58 EDT","volume":1585854,"amount":65053645.3871,"timestamp":1778540300320,"change":0.05,"changeRate":0.001219,"amplitude":0.001463},"delay":0,"changeRate":-0.00024372410431386816,"floatShares":78119932,"shares":127829909,"eps":1.026155,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"05-11 16:00:00 EDT","open":41.03,"high":41.06,"low":41.02,"amount":370164493.0752,"amplitude":0.000975,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.026155,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778572800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":41.03,"preHourTrading":{"tag":"盘前","latestPrice":41.03,"preClose":41.03,"latestTime":"09:29 EDT","volume":584268,"amount":23972582.062284,"timestamp":1778506199999,"change":0,"changeRate":0,"amplitude":0.001219},"postHourTrading":{"tag":"盘后","latestPrice":41.07,"preClose":41.02,"latestTime":"18:58 EDT","volume":1585854,"amount":65053645.3871,"timestamp":1778540300320,"change":0.05,"changeRate":0.001219,"amplitude":0.001463},"volumeRatio":1.838557,"impliedVol":0.0283,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"2634418402","title":"Is It Too Late To Consider Apellis Pharmaceuticals (APLS) After Its 130% One Year Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2634418402","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634418402?lang=en_us&edition=fundamental","pubTime":"2026-05-09 18:31","pubTimestamp":1778322701,"startTime":"0","endTime":"0","summary":"If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value.\nThe stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/is-it-too-late-to-consider-apellis-pharmaceuticals-apls-afte","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/is-it-too-late-to-consider-apellis-pharmaceuticals-apls-afte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","APLS","LU1093756168.USD","BK4139","DCF","BK4588","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633087281","title":"S&P Dow Jones Indices : Bright Horizons Family Solutions and Remitly Global Set to Join S&P Smallcap 600","url":"https://stock-news.laohu8.com/highlight/detail?id=2633087281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633087281?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:02","pubTimestamp":1778191365,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K1MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4227","BK4585","BK4505","LU1093756168.USD","LU0053671581.USD","RELY","BK4139","BK4106","APLS","BK4588","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633570143","title":"Apellis Q1 FY26 swings to net income of $18.66 million; revenue rises 61% to $268.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633570143","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633570143?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:57","pubTimestamp":1778151426,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals swung to net income of USD 18.66 million as revenue climbed 61% to USD 268.3 million.Net product revenue rose 28% to USD 192.01 million, led by SYFOVRE at USD 150.7 million and EMPAVELI at USD 41.3 million.Licensing and other revenue more than tripled to USD 76.29 million, including USD 25 million tied to Royalty Agreement and USD 30 million in regulatory development milestones.Operating income totaled USD 26.47 million as research and development expense fell 11% to USD 76.96 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLNgBcN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4505","LU0320765992.SGD","LU1093756325.SGD","APLS","BK4532","BK4533","BIIB","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0109394709.USD","BK4585","LU0234570918.USD","LU0889565916.HKD","BK4139","LU1093756168.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632374309","title":"Apellis amends executive separation plan to accelerate vesting on termination pre-close","url":"https://stock-news.laohu8.com/highlight/detail?id=2632374309","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632374309?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:07","pubTimestamp":1777892827,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals compensation committee set amendment and restatement of Executive Separation Benefits and Retention Plan, tied to merger agreement with Biogen.Plan becomes effective on closing date of transaction.Unvested rights to payments for Converted Options and Converted RSU Awards would accelerate and fully vest if participant is terminated without cause or resigns for good reason before vesting.Good Reason definition change removes carve-out for post-merger scope changes for C-level officers, including named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8kzSJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BIIB","APLS","BK4532","LU1093756325.SGD","LU0889565916.HKD","BK4533","BK4505","IE00B894F039.SGD","BK4139","IE00B19Z9P08.USD","BK4585","BK4588","LU0320765992.SGD","LU0109394709.USD","LU1093756168.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631682969","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2631682969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631682969?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:00","pubTimestamp":1777543200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A. O. Smith Corp                                 1Q       .94    6:55 AM. ·Air Prod & Chem                                  2Q      3.06    6:00 AM. ·Altria Grp Inc                                    1Q      1.25    7:00 AM. ·APi Grp Corp                                     1Q       .30    7:30 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOOM","AUPH","AVTX","AXTI","BDC","APG","ADT","AMGN","AJG","BBIO","BAND","APLS","AIG","ARDX","BAX","ALDX","BC","ATI","ATR","ALNY","AME","ACA","BLDR","AEM","ALHC","ASUR","BIO","BBVA","ALEC","BR","BCYC","CABO","AX","ARVN","AXTA","ASND","BZH","AOS","BSAC","AUTL","BIO.B","AAPL","BFLY","AES","BMY","CAH","ACCO","APD","AIN","ANGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631599479","title":"Biogen cuts annual profit forecast on acquisition-related charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2631599479","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631599479?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:03","pubTimestamp":1777456992,"startTime":"0","endTime":"0","summary":"Biogen cuts annual profit forecast on acquisition-related charges April 29 (Reuters) - Biogen BIIB.O cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL4N41C0D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","APLS","IE00B19Z9Z06.USD","LU0320765992.SGD","LU1093756168.USD","LU0234570918.USD","LU1093756325.SGD","IE00B894F039.SGD","BK4533","LU0109394709.USD","BK4588","BK4532","BK4139","BK4505","BK4585","BIIB","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631599433","title":"Biogen Q1 FY26 GAAP EPS jumps 31% to $2.15; revenue climbs 2% to $2.5 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2631599433","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631599433?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:01","pubTimestamp":1777456905,"startTime":"0","endTime":"0","summary":"Biogen posted Q1 2026 net income of USD 319.5 million, up 33%.GAAP diluted EPS climbed 31% to USD 2.15.LEQEMBI global in-market sales jumped 74% to USD 168 million; SPINRAZA global revenue fell 12% to USD 374 million.Biogen highlighted a proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027, and guided for 2026 non-GAAP diluted EPS of USD 14.25 to USD 15.25 with revenue projected to decline by a mid-single digit percentage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL9h6DLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0320765992.SGD","BK4588","APLS","IE00B19Z9Z06.USD","LU1093756168.USD","BK4585","BIIB","BK4505","BK4139","BK4532","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628206864","title":"Wells Fargo Downgrades Apellis Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $41 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2628206864","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628206864?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:14","pubTimestamp":1776428063,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1093756325.SGD","BK4505","APLS","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749032","title":"Apellis downgraded to Equal Weight from Overweight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628749032?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:20","pubTimestamp":1776417613,"startTime":"0","endTime":"0","summary":"Wells Fargo downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26. Published first on TheFly – the ulti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930490.SGD","LU2461242641.AUD","LU1093756325.SGD","LU0106831901.USD","LU0149725797.USD","LU2236285917.USD","BK4588","LU0742534661.SGD","LU0320765489.SGD","LU0310800379.SGD","LU0208291251.USD","LU0130102774.USD","BK4207","LU0971096721.USD","LU0154236417.USD","LU1093756168.USD","LU0052756011.USD","LU1791807156.HKD","LU1035773651.USD","IE0002270589.USD","LU0980610538.SGD","LU1506573853.SGD","LU0708994859.HKD","LU0128525929.USD","LU1894683348.USD","LU0417517546.SGD","LU1267930573.SGD","LU0175139822.USD","LU0787776722.HKD","LU1074936037.SGD","LU1267930227.SGD","BK4139","LU0868494708.USD","LU1894683264.USD","BK4559","LU1363072403.SGD","LU0072461881.USD","LU0130517989.USD","LU0211328371.USD","LU1201861249.SGD","BK4501","APLS","LU0048573561.USD","LU0267386448.USD","LU0942090050.USD","LU0310799852.SGD","LU0683600562.USD","IE00B7SZLL34.SGD","LU0289960550.SGD","LU2361044865.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627235197","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627235197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627235197?lang=en_us&edition=fundamental","pubTime":"2026-04-15 22:50","pubTimestamp":1776264608,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY) and Apellis Pharmaceuticals (APLS). Alnylam...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","ALNY","LU0889565916.HKD","BK4137","BK4581","XLV","LABU","XBI","BK4548","BK4585","LU0320765992.SGD","LU0029874061.USD","LU1093756325.SGD","LU0128526141.USD","BK4588","LU1093756168.USD","BK4505","BK4139","LU0882574055.USD","LU0114720955.EUR","APLS","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627590784","title":"BUZZ-Citi, Truist trim PT on Biogen ahead of Q1 earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2627590784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627590784?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:36","pubTimestamp":1776090969,"startTime":"0","endTime":"0","summary":"BUZZ-Citi, Truist trim PT on Biogen ahead of Q1 earnings** Citi maintains a \"neutral\" rating on Biogen BIIB.O shares and cuts price target to $190 from $215** Truist Securities maintains \"hold\" rating on the stock and cuts PT to $189 from $193** Truist says its lower target mainly reflects the expected financial impact of BIIB's $5.6 billion Apellis APLS.O deal, including forecasts for APLS' approved drugs Syfovre and Empaveli** \"Turnaround still in motion, but execution remains the proof point\" - Citi ** Says BIIB's Alzheimer's drug Leqembi remains the main growth story, but sales will likely rise only gradually even after U.S. FDA clears a self-injection version of the drug in May** Adds that uptake will be slow, given brain scans are likely what doctors prefer for amyloid confirmation** Newer drugs such as Skyclarys and Zurzuvae should support growth while older drugs remain under pressure - Citi** BIIB shares up 0.9% at $174.54** Including session's move, BIIB down 0.8% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W16H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930227.SGD","LU2360032135.SGD","LU0072461881.USD","LU0052756011.USD","LU0162691827.USD","LU1791807156.HKD","LU1244550577.SGD","LU1668664300.SGD","LU0234570918.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0128525689.USD","LU0648001328.SGD","BK4505","BK4139","LU0109394709.USD","BK4504","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0477156953.USD","LU2417539215.USD","LU0170899867.USD","BK4534","LU1162221912.USD","LU0320765992.SGD","LU2125154778.USD","APLS","BK4585","LU0130517989.USD","LU1244550221.USD","LU0320765646.SGD","LU1201861249.SGD","LU0314106906.USD","BK4207","LU1244550494.USD","LU2456880835.USD","IE00BSNM7G36.USD","LU2125154935.USD","LU1093756325.SGD","BK4559","BK4533","LU1093756168.USD","LU2236285917.USD","BIIB","BK4532","LU0106831901.USD","LU0980610538.SGD","BK4566","LU0098860793.USD","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953097","title":"RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953097","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953097?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:05","pubTimestamp":1775567107,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $39.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BK4588","BK4585","APLS","BK4139","LU1093756168.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625293454","title":"Apellis Pharmaceuticals Inc : RBC Raises Target Price to $41 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2625293454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625293454?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:33","pubTimestamp":1775557981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q0OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APLS","LU1093756168.USD","BK4588","BK4505","BK4585","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625933307","title":"U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2625933307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625933307?lang=en_us&edition=fundamental","pubTime":"2026-04-07 16:04","pubTimestamp":1775549040,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO April 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspac","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKNG","AJG","APLE","AN","CVNA","OZK","BX","BWIN","ASB","CNC","CBOE","CNCG","AU","AXP","BIIB","BOKF","CELH","ABG","BOH","AA","CVNX","ANET","BKNU","AMZY","AMP","AMZW","TXG","COF","BOW","AX","AKAM","BAC","BANC","ARRY","AEIS","APLS","CELT","AMGN","AMZP","BKU","BIO","BRBR","CSR","BKR","ARCB","AMZN","AMZD","SAM","AMZU","CVNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675079","title":"Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675079","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675079?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:40","pubTimestamp":1775472000,"startTime":"0","endTime":"0","summary":"Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/06/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/06/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/26/04/51653630/apellis-stock-soars-after-biogen-deal-momentum-score-surges-heres-what-shareholders-get","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/26/04/51653630/apellis-stock-soars-after-biogen-deal-momentum-score-surges-heres-what-shareholders-get","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4533","IE00B19Z9Z06.USD","LU0234570918.USD","LU0889565916.HKD","BK4505","BK4585","LU0320765992.SGD","LU1093756168.USD","BK4588","LU1093756325.SGD","IE00B19Z9P08.USD","SLNO","LU0109394709.USD","IE00B894F039.SGD","BK4139","APLS","BK4532","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669875","title":"The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669875?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266200,"startTime":"0","endTime":"0","summary":"Big Pharma companies are constantly searching for the next hot new drugs -- and it's often a lot easier to buy them than develop them. That's great news for biotech investors. Merger activity is starting to heat up again in the sector.There were three notable deals in March alone. Biogen just announced a deal to buy Apellis Pharmaceuticals, a developer of immunological and rare-disease medications, for $5.6 billion, a takeover premium of nearly 140%. Mounjaro owner Eli Lilly is buying sleep-drug maker Centessa Pharmaceuticals for $7.8 billion. And Merck said it would buy Terns Pharmaceuticals, which is working on a drug to treat leukemia, for $6.7 billion.Mergers won't be the only catalyst for biotechs. Analysts at Cantor Fitzgerald pointed out in a report in March that they expect about 80% of the companies in the State Street SPDR S&P Biotech ETF will have approved drugs by the third quarter of next year. This, according to Cantor, suggests the industry is \"still early in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU0889565916.HKD","BK4585","APLS","LU1093756168.USD","LU2324357040.USD","STT","IE00B3QW5Z07.USD","BK4588","CNTA","BK4535","LU1883839398.USD","ARGX","IE00BJT1NW94.SGD","IE00BGHQF748.EUR","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU1983260115.SGD","BK4539","KALV","TERN","BK4135","LU1093756325.SGD","LU0109394709.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1894683264.USD","BK4505","BK4007","LU0061475181.USD","IE0009355771.USD","IE0034235188.USD","IE00B64PRP62.GBP","IE00B4R5TH58.HKD","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624662737","title":"Build More New Houses -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2624662737","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624662737?lang=en_us&edition=fundamental","pubTime":"2026-04-04 06:10","pubTimestamp":1775254200,"startTime":"0","endTime":"0","summary":"The Census Bureau's latest population estimates illustrate how housing supply supports -- or stunts -- growth. More than two-thirds of metro areas in June 2025 had fewer listings than in 2019, before the pandemic supercharged housing and rising mortgage rates pushed buyers and sellers to the sidelines. But of the 10 fastest-growing metropolitan areas in 2025, nine had more homes for sale than before the pandemic, a Barron's analysis of Realtor.com and government data suggest.The central Florida metro of Ocala had the biggest population percentage gain in the U.S. last year, per Census estimates, followed by Myrtle Beach and Spartanburg, S.C. Listings in No. 6 Huntsville, Ala., were 78% higher than in 2019. \"What [the data] does tell us is that there is still demand for housing in more affordable parts of the country,\" says Eric Finnigan, vice president of demographics research at John Burns Research and Consulting.Unilever announced a $44.8 billion deal with McCormick to merge food ope","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJLML261.HKD","LU0310799852.SGD","LU2237443382.USD","LU1366192091.USD","LU1043141396.HKD","LU2125909247.SGD","IE000SO60NU8.SGD","LU1778281490.HKD","LU0070217475.USD","LU0345769128.USD","LU0079474960.USD","LU0823421416.USD","GGLS","IE00BZ199S13.USD","LU2242650005.HKD","LU0316494557.USD","LU2264538146.SGD","GOOP","LU0203201768.USD","BK4581","LU1951198990.SGD","IE0009355771.USD","LU0077335932.USD","LU2360106780.USD","LU0889565916.HKD","LU0690374961.EUR","LU0784385170.HKD","IE0000B7K699.USD","LU0158827948.USD","LU0348723411.USD","LU2023250504.SGD","LU2168564065.EUR","LU2491050071.SGD","LU0787776722.HKD","LU2168564222.USD","LU0068578508.USD","LU0256863811.USD","LU0784384876.USD","IE00B4JS1V06.HKD","LU0964807845.USD","LU1935042991.SGD","LU0494093205.USD","LU0061474960.USD","LU1803068623.USD","LU0788109477.HKD","LU0640476718.USD","LU2237443978.SGD","IE00BK4W5L77.USD","IE00BYXW3230.USD","LU0056508442.USD","LU0823434740.USD","LU0957808578.USD","IE00B19Z9P08.USD","LU2756315318.SGD","LU2746668461.USD","BK4548","SG9999015952.SGD","LU0823434583.USD","SG9999015945.SGD","LU0011850046.USD","IE00BKDWB100.SGD","BK4503","LU1032955483.USD","LU0345768153.USD","LU2028103732.USD","IE00BJTD4N35.SGD","LU0130103400.USD","IE00BFXG0V08.USD","SG9999015978.USD","LU1551013425.SGD","LU1035775433.USD","BIIB","LU0784385840.USD","LU0211326755.USD","LU0949170426.SGD","LU0417517546.SGD","LU0882574055.USD","LU1791710582.SGD","LU2271345857.HKD","BK4554","LU0072462426.USD","IE00BFSS8Q28.SGD","BK4525","LU0124676726.USD","LU0496365809.HKD","LU2360106947.USD","LU0314106906.USD","LU0444971666.USD","LU1935043023.USD","LU1868836914.USD","LU2063271972.USD","LU1571399168.USD","LU1914381329.SGD","MKC","IE00B894F039.SGD","LU1323610961.USD","LU0149725797.USD","LU0354030438.USD","IE00BBT3K403.USD","IE00B7SZLL34.SGD","LU0256863902.USD","LU1267930227.SGD","LU2458330169.SGD","BK4579","LU0096364046.USD","IE000M9KFDE8.USD","LU0238689110.USD","LU2098885051.SGD","IE00BKPKM429.USD","LU1196500208.SGD","LU2471134796.USD","SG9999017495.SGD","IE0034235303.USD","LU2237443622.USD","LU0648000940.SGD","SGXZ99366536.SGD","LU0251132253.USD","LU0823416689.USD","BK4612","LU2236285917.USD","LU0784383803.USD","IE0004091025.USD","LU1923623000.USD","LU0053666078.USD","LU0861579265.USD","LLYZ","LU2746668974.SGD","LU0234570918.USD","LU0096362180.USD","SGXZ81514606.USD","LU0061474705.USD","LU2468319806.SGD","BK4507","LU0203347892.USD","LU2433249047.HKD","LU2764263203.CNY","LU1989772923.USD","LU2054465674.USD","LU1699723380.USD","LU1116320901.HKD","IE00B5949003.HKD","LU0106261372.USD","LU0889565833.HKD","LU1983299246.USD","LU2326559502.SGD","IE0034235295.USD","LU2756315664.SGD","LU0957791311.USD","GB00BDT5M118.USD","APLS","IE00BLSP4239.USD","BK4543","LU0211331839.USD","LU1043141123.HKD","LU1951200564.SGD","LU0323591593.USD","LU2065171311.SGD","LU0080751232.USD","LU1934455194.USD","BK4602","LU0310800965.SGD","LU0320765489.SGD","IE00B1BXHZ80.USD","LU1301847155.USD","LU2089284900.SGD","LU2089283258.USD","GOOY","BK4588","LU0130102774.USD","LU0265550359.USD","LU1023059063.AUD","GGLL","LU0719512351.SGD","SG9999015986.USD","LU0058720904.USD","LU1244550494.USD","LU0302445910.USD","LU1923622614.USD","LU1988902786.USD","LU1645745479.HKD","GB00B4QBRK32.GBP","LU2087621335.USD","LU2362540622.SGD","LU1127390331.HKD","LU2471134523.USD","LU2403377893.USD","LU0094547139.USD","LU2237443465.HKD","LU1917777945.USD","LU1280957306.USD","LU1430594728.SGD","IE0005OL40V9.USD","IE00B19Z8X17.USD","LU2244417387.USD","IE00BYQQ9H92.USD","LU0157215616.USD","LU2463028550.USD","BK4077","LU2211815571.USD","LU1823568750.SGD","LU1691799644.USD","IE0004445015.USD","LU2023250843.SGD","LU2092937148.SGD","LU0545039389.USD","LU0477156797.USD","LU0385154629.USD","LU1815336760.USD","IE00BJJMRX11.SGD","LU2065170008.USD","LU2430703178.SGD","LU0127658192.USD","IE00BN29S564.USD","USJW.SI","SG9999018857.SGD","LU0345769631.USD","LU2750360997.AUD","LU0471298777.SGD","LU1674673428.USD","SG9999001077.SGD","LU2430703095.HKD","LU2092627202.USD","LU0354030511.USD","LU1201861165.SGD","LU1267930813.SGD","LU0203202063.USD","LU0320765992.SGD","LU0889566641.SGD","LU0976567544.SGD","IE00BDCRKT87.USD","BK4585","BK4553","LU0210528500.USD","BK4527","LU0211326839.USD","LU0289739699.SGD","LU1069347547.HKD","LU1119994496.HKD","SG9999001176.SGD","LU1551013342.USD","LU0553294199.USD","LU2213496289.HKD","IE00BJJMRY28.SGD","IE00B2B36J28.USD","LU2860962120.EUR","IE00B19Z9505.USD","SG9999013999.USD","LU1814569148.SGD","IE0001KFT4U8.USD","LU0128525689.USD","LU1061106388.HKD","LU1244550221.USD","SG9999014880.SGD","LU0215105999.USD","LU2097829019.USD","BK4514","LU1066051811.HKD","LU1202635105.USD","LU1316542783.SGD","LU1670627923.USD","IE00BFSS7M15.SGD","LU2286300806.USD","LU0225283273.USD","LU1303367103.USD","LU1894683348.USD","LU0661504455.SGD","LU1868837136.USD","LU2168564495.EUR","LU2089984988.USD","IE00B19Z3581.USD","IE00BJTD4V19.USD","SGXZ31699556.SGD","NKE","LU0444973449.USD","LU0433182093.SGD","BK4538","LU2602419157.SGD","LU1093756325.SGD","IE00BDRTCR15.USD","IE00BMPRXQ63.HKD","LU0052756011.USD","LU0251131958.USD","LU0689626769.HKD","LU1291159041.SGD","LU2237443895.HKD","GB00B4LPDJ14.GBP","LU2362541273.HKD","LU1974910355.USD","LU2023250330.USD","LU0786609619.USD","HK0000304797.USD","LU0048584097.USD","IE00BLSP4452.SGD","LU1670628061.USD","LU1868837300.USD","LU1057294990.SGD","LU0109394709.USD","LU2592432038.USD","LU0158827781.USD","LU0708994859.HKD","BK4574","LU0820561909.HKD","LU0138981039.USD","LU0985320562.USD","LU2471134952.CNY","LU0882574139.USD","LU1066051225.USD","IE00B19Z3B42.SGD","LU0048573561.USD","LU1221951129.SGD","BK4533","LU2168563687.JPY","LU1064131342.USD","LU1674673691.USD","LU0276348264.USD","LU0234572021.USD","LU0690374615.EUR","BK4550","LU1880398471.USD","LU1074936037.SGD","LU0082616367.USD","LU1623119135.USD","IE0004445239.USD","LU1066051498.USD","BK4007","LU1935042488.USD","LU2357305700.SGD","LU0868494708.USD","LU0208291251.USD","IE00B1XK9C88.USD","LU1221951046.USD","LU0868494617.USD","IE00B775SV38.USD","LU1145028129.USD","LU0320765059.SGD","LU1633808545.USD","LU1506573853.SGD","LU2456880835.USD","LU2491049909.HKD","LU1059921491.USD","GOU","LU0345770308.USD","LU1153585028.USD","LU1839511570.USD","IE000WAW04H5.SGD","IE00BMPRXN33.USD","LU0942090050.USD","IE00BFTCPJ56.SGD","LU0708995401.HKD","BK4592","LU2250418816.HKD","LU2361044949.HKD","LU0683600562.USD","IE00BQXX3C00.GBP","LU2505996681.GBP","LU2097344431.USD","LU2458330243.SGD","LU0528227936.USD","LU1116320737.USD","LU1712237335.SGD","LU0466842654.USD","LU0211328371.USD","IE00BMPRXR70.SGD","IE0009356076.USD","GOOGL","LU0314104364.USD","LU1989764748.USD","SG9999002232.USD","LU0289960550.SGD","LU1670756490.USD","IE00BWXC8680.SGD","IE00BK4W5M84.HKD","LU0426412945.USD","LU1629891620.HKD","LU1894683264.USD","LU0154236417.USD","IE00BSNM7G36.USD","LU0432979614.USD","LU0994945656.USD","IE00BHPRN162.USD","LU2077746001.SGD","LU1400636657.SGD","LU1400636491.USD","IE00BZ1G4Q59.USD","IE00B775H168.HKD","IE00BKVL7J92.USD","LU0965509283.SGD","LU2552382215.SGD","LU2552382058.USD","IE000BZT7R73.USD","LU0170899867.USD","LU1235294995.USD","LU2462157665.USD","SGXZ51526630.SGD","LU1261432733.SGD","IE00B4R5TH58.HKD","LU1066053197.SGD","SGXZ57979304.SGD","IE000MB6IJN5.SGD","LU2764263039.SGD","LU0742534661.SGD","LU0175139822.USD","LU0070302665.USD","LU0187121727.USD","LU1989772840.SGD","LU1548497426.USD","UL","LU0210536198.USD","LU1121112475.USD","LU0130518102.USD","LU0265550946.USD","SG9999002224.SGD","LU0310800379.SGD","BK4534","IE0034235188.USD","LU0128525929.USD","LU0345774631.USD","LU1642822529.SGD","BK4139","LU1868836591.USD","LU1852331112.SGD","LU2461242641.AUD","LU2237443549.SGD","LU1435385759.SGD","SG9999018865.SGD","LU0251142724.SGD","LU1791710400.SGD","LU2111349929.HKD","LU0792757196.USD","LU1585245621.USD","LU2404859741.USD","LU2750360641.GBP","BK4599","LU2764262908.HKD","LU2087625088.SGD","BK4505","LU0289941410.SGD","LU0312595415.SGD","LU0203345920.USD","IE00B3S45H60.SGD","LU1496350171.SGD","LU1720051017.SGD","LU1935043536.SGD","BK4532","LU0114720955.EUR","LU2275660780.HKD","LU1003077747.HKD","LU2491050154.USD","IE00BFMHRM44.USD","LU0029864427.USD","LU2543165471.USD","LU1804176565.USD","BK4587","LU0122379950.USD","LU0345768740.USD","LU1232071149.USD","LU1489326972.SGD","LU0943347566.SGD","LU2430703251.USD","LU0109391861.USD","LLII","IE00B5TLWC47.USD","LU2505996509.AUD","IE000F7OJYX1.SGD","GOOX","LU1093756168.USD","LU2106854487.HKD","LU0642271901.SGD","LU0353189680.USD","LU0820562030.AUD","LU0648001328.SGD","LU0965509010.AUD","LU1935042215.USD","LU1429558221.USD","LU1934455277.USD","LLYX","LU0210533765.USD","LU1244550577.SGD","LU2381873111.SGD","LU1868836757.USD","LU1069344957.HKD","LU0476273544.USD","SG9999000418.SGD","LU2108987350.USD","IE00BJT1NW94.SGD","LU1496350502.SGD","LU2324357040.USD","LU0061475181.USD","LU2023251221.USD","LU1720051108.HKD","LU0689472784.USD","LU0345770993.USD","LU1267930730.SGD","LU0342679015.USD","LU2361044865.SGD","LU2125154778.USD","LU2552382132.HKD","LU2420271590.USD","LU0345774391.USD","LU1035773651.USD","LU1989771016.USD","LU2417539215.USD","LU2362541513.USD","LU0471298694.HKD","ELIS","BK4561","LU0308772762.SGD","LU2265009873.SGD","LU2237438978.USD","BK4576","BK4566","LU2125154935.USD","LU2191332357.HKD","SG9999014898.SGD","LU1815333072.USD","GOOW","LU1267930573.SGD","LU2720916845.USD","LU0724617625.USD","LU1037948897.HKD","IE00B19Z9Z06.USD","BK4516","LU1934455863.HKD","LU1400636574.HKD","LU0097036916.USD","LU1267930490.SGD","IE00BN8TJ469.HKD","IE00B19Z8W00.USD","SG9999014914.USD","LU1803068979.SGD","LU0738911758.USD","LU0107464264.USD","LU1366333091.USD","LU0949170772.SGD","LU0823421333.USD","LU0266013472.USD","LU1084165304.USD","LU2242649171.HKD","IE0004086264.USD","LU2125909593.SGD","LU2112291526.USD","SG9999001176.USD","LLY","IE0002141913.USD","LU0985489474.SGD","IE00BQXX3F31.USD","LU0211327993.USD","LU1201861249.SGD","IE0002270589.USD","LU0426417589.USD","IE00B7KXQ091.USD","LU2361045086.USD","LU2487616109.SGD","LU0878866978.SGD","LU1880398554.USD","LU0456855351.SGD","LU2896262040.SGD","HK0000304805.HKD","LU0672654240.SGD","LU0965508806.USD","LU1046421795.USD","LU1718418525.SGD","LU0965509101.SGD","BK4573","IE00BQXX3D17.EUR","LU0198837287.USD","LU2065171402.SGD","LU2168564149.EUR","LU2471134879.HKD","LU0353189763.USD","LU1037948541.HKD","LU0109392836.USD","LU0980610538.SGD","BK4598","LU0006306889.USD","LU2097344357.USD","LU0267386448.USD","LU2247934214.USD","LU2404859667.USD","SG9999014906.USD","ELIL","LU0130517989.USD","IE00BJJMRZ35.SGD","LU0820561818.USD","LU0477156953.USD","LU1989764664.SGD","LU2065169927.USD","LU2360032135.SGD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624508565","title":"Apellis Pharmaceuticals Inc : Mizuho Raises Target Price to $41 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2624508565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624508565?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:37","pubTimestamp":1775126251,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU1093756325.SGD","BK4585","LU1093756168.USD","APLS","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624571205","title":"Apellis downgraded to Neutral from Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2624571205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624571205?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:31","pubTimestamp":1775118661,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Adam Walsh downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, up from $31, following Biogen’s (BIIB) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9P08.USD","APLS","IE00B19Z9Z06.USD","LU0320765992.SGD","LU1093756168.USD","LU0234570918.USD","LU1093756325.SGD","IE00B894F039.SGD","BK4533","LU0109394709.USD","BK4588","BK4532","BK4139","BK4505","BK4585","BIIB","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624575278","title":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2624575278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624575278?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:21","pubTimestamp":1775114493,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United TherapeuticsApril 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DIN","BAH","GOOY","CEG","CFG","STZ","USAW.SI","CSL","GENK","GPN","AZYY","XOM","XOMZ","DASX","BARK","BAC","CAVA","FBK","BOH","GOOX","GOU","ALAB","DASH","FBIN","COP","GGLL","BJRI","BETA","GOOW","GOOP","APLS","BYND","CACI","GD","GE","CQP","CW","DK","CVX","DCO","AROC","LNG","CAG","AMZN","GOOGL","CVI","CTRE","ANRO","BHVN","BA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.0056},{"period":"3month","weight":0.8167},{"period":"6month","weight":1.049},{"period":"1year","weight":1.3711},{"period":"ytd","weight":0.633}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.0881},{"period":"3month","weight":0.0682},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.31},{"period":"ytd","weight":0.0841}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.555556,"avgChangeRate":0.020983},{"month":3,"riseRate":0.555556,"avgChangeRate":0.121941},{"month":4,"riseRate":0.666667,"avgChangeRate":0.037338},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.032565},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}